3 results
Approved WMORecruiting
Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…
Approved WMOCompleted
The primary objective is to determine the effect of high-dose sunitinib versus standard treatment with lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria. Secondary objectives are:1. To…
Approved WMOCompleted
To compare the safety and efficacy of the Tack Endovascular System* in subjects with peripheral artery disease (PAD) to a pre-defined performance goal (PG).